Quarterly report · Q1
9273.TEDINET S100PM9S
Period2022-07-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.4bn | 2022-07-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥20.4bn | 2021-07-01 → 2022-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.8bn | 2021-07-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥1.0bn | 2022-07-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥871m | 2021-07-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥979m | 2022-07-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.8bn | 2021-07-01 → 2022-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥876m | 2021-07-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥979m | 2022-07-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥876m | 2021-07-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥606m | 2022-07-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.4bn | 2021-07-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥606m | 2021-07-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥606m | 2022-07-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥606m | 2021-07-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥26.3bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥26.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥24.6bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.4bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥7.6bn | at 2022-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥18.8bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥18.7bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥16.9bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.6bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.1bn | at 2022-06-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥15.29 | 2022-07-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.55 | 2021-07-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.29 | 2021-07-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 71.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.1% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.8% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥501m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥501m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | ¥6m |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥3.5bn |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥501m |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥672m |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥337m |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥5.9bn |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥5.4bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥501m |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥1.0bn |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2021-09-30 | −¥498m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2021-09-30 | −¥498m |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2021-09-30 | −¥803,000 |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥3.6bn |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥3.1bn |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥498m |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥609m |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥1.7bn |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥1.7bn |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥262m |
| —segment total | revenue | 2021-07-01 → 2021-09-30 | ¥5.3bn |
| —segment total | revenue external | 2021-07-01 → 2021-09-30 | ¥4.8bn |
| —segment total | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥498m |
| —segment total | segment profit | 2021-07-01 → 2021-09-30 | ¥871m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 353
| Item | Context | Value | Unit |
|---|---|---|---|
| Income taxes current | Prior1YTDDuration | 267060000 | JPY |
| Income taxes current | CurrentYTDDuration | 352795000 | JPY |
| Income taxes deferred | Prior1YTDDuration | 2988000 | JPY |
| Income taxes deferred | CurrentYTDDuration | 20619000 | JPY |
| Income taxes | Prior1YTDDuration | 270049000 | JPY |
| Income taxes | CurrentYTDDuration | 373415000 | JPY |
| Profit loss | Prior1YTDDuration | 605913000 | JPY |
| Profit loss | CurrentYTDDuration | 605900000 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | 605913000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | 605900000 | JPY |
| Profit loss | Prior1YTDDuration | 605913000 | JPY |
| Profit loss | CurrentYTDDuration | 605900000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | 2757000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | 260000 | JPY |
| Deferred gains or losses on hedges net of tax oci | Prior1YTDDuration | 13897000 | JPY |
| Deferred gains or losses on hedges net of tax oci | CurrentYTDDuration | -1304000 | JPY |
| Other comprehensive income | Prior1YTDDuration | 16655000 | JPY |
| Other comprehensive income | CurrentYTDDuration | -1044000 | JPY |
| Comprehensive income | Prior1YTDDuration | 622569000 | JPY |
| Comprehensive income | CurrentYTDDuration | 604856000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 622569000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 604856000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 3097308000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 1748465000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 4845773000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 4845773000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 497754000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 497754000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -497754000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 3595062000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 1748465000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 5343528000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -497754000 | JPY |
| Net sales | Prior1YTDDuration | 4845773000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 608932000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 262406000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 871338000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -803000 | JPY |
| Operating income | Prior1YTDDuration | 870534000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 3465704000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 1892904000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 5358608000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 5358608000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 501364000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 501364000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |